Literature DB >> 17405918

Modification of proteins by cyclopentenone prostaglandins is differentially modulated by GSH in vitro.

Javier Gayarre1, M Isabel Avellano, Francisco J Sánchez-Gómez, M Jesús Carrasco, F Javier Cañada, Dolores Pérez-Sala.   

Abstract

Prostanoids with cyclopentenone structure (cyP) display a potent anti-inflammatory and antiproliferative activity. CyP are reactive compounds, which may modulate cellular functions by multiple mechanisms, including the direct covalent modification of cysteine residues by Michael addition. This interaction displays selectivity since only a subset of cellular proteins is modified by cyP. Several factors have been proposed to influence the selectivity and/or extent of cyP addition to proteins, including determinants related to protein and cyP structure, and levels of cellular thiols, such as glutathione (GSH). Here we have explored the ability of biotinylated cyP analogs to modify several recombinant proteins in vitro, and the influence of GSH in these effects. We have observed that protein modification by cyP is protein- and cyP-selective. Under our conditions, biotinylated 15-deoxy-Delta(12,14)-PGJ(2) (15d-PGJ(2)-B) was more efficient than biotinylated PGA(1) (PGA(1)-B) at forming adducts with components of the transcription factors NF-kappaB and activator protein-1 (AP-1). However, both biotinylated cyP were nearly equipotent at modifying human GSTP1-1. Interestingly, the presence of GSH differentially modulated the formation of protein-cyP adducts. Under our conditions, GSH reduced the incorporation of cyP into GST, but improved their binding to p50, more intensely in the case of PGA(1)-B. These results evidence the importance of GSH-cyP and/or GSH-protein interactions for the selectivity of protein modification by cyP and suggest a complex role for GSH that may be related to its ability to prevent protein oxidation or induce conformational alterations. This may shed light on the factors involved in the pleiotropic effects of electrophiles with therapeutic potential.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17405918     DOI: 10.1196/annals.1397.072

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  6 in total

1.  Cyclopentenone prostaglandin-induced unfolding and aggregation of the Parkinson disease-associated UCH-L1.

Authors:  Leonardus M I Koharudin; Hao Liu; Roberto Di Maio; Ravindra B Kodali; Steven H Graham; Angela M Gronenborn
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-15       Impact factor: 11.205

2.  Prostaglandin A1 Decreases the Phosphorylation of Tau by Activating Protein Phosphatase 2A via a Michael Addition Mechanism at Cysteine 377.

Authors:  Guo-Biao Xu; Pei-Pei Guan; Pu Wang
Journal:  Mol Neurobiol       Date:  2020-10-23       Impact factor: 5.590

3.  Accumulation of 15-deoxy-delta(12,14)-prostaglandin J2 adduct formation with Keap1 over time: effects on potency for intracellular antioxidant defence induction.

Authors:  Joo Yeun Oh; Niroshini Giles; Aimee Landar; Victor Darley-Usmar
Journal:  Biochem J       Date:  2008-04-15       Impact factor: 3.857

4.  15-Deoxy-Δ12,14-Prostaglandin J2 Modifies Components of the Proteasome and Inhibits Inflammatory Responses in Human Endothelial Cells.

Authors:  Simone Marcone; Paul Evans; Desmond J Fitzgerald
Journal:  Front Immunol       Date:  2016-10-27       Impact factor: 7.561

Review 5.  Lipoxidation and cancer immunity.

Authors:  C Martín-Sierra; P Laranjeira; M R Domingues; A Paiva
Journal:  Redox Biol       Date:  2019-01-11       Impact factor: 11.799

6.  Regulation of signal transduction by glutathione transferases.

Authors:  Julie Pajaud; Sandeep Kumar; Claudine Rauch; Fabrice Morel; Caroline Aninat
Journal:  Int J Hepatol       Date:  2012-10-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.